Liu Jidan, Gong Juanfen, Xu Jinchao, Fang Mengyuan, Su Meng, Li Weiguang, Wu Yiyi, Hui Yang, He Yingchun
Department of Geriatrics, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang, China.
Department of Sports Medicine, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350000, Fujian, China.
Evid Based Complement Alternat Med. 2023 Jan 18;2023:9021546. doi: 10.1155/2023/9021546. eCollection 2023.
Vascular dementia (VD), associated with cerebrovascular injury, is characterized by severe cognitive impairment. Jianpi Tianjing Decoction (JTD) has been widely used to treat VD. However, its molecular targets and mechanisms of action in this treatment remain unclear. This study integrated network pharmacology and proteomics to identify targets and mechanisms of JTD in the treatment of VD and to provide new insights and goals for clinical treatments.
Systematic network pharmacology was used to identify active chemical compositions, potential targets, and mechanisms of JTD in VD treatment. Then, a mouse model of VD was induced via transient bilateral common carotid artery occlusion to verify the identified targets and mechanisms of JTD against VD using 4D label-free quantitative proteomics.
By screening active chemical compositions and potential targets in relevant databases, 187 active chemical compositions and 416 disease-related compound targets were identified. experiments showed that JTD improved learning and memory in mice. Proteomics also identified 112 differentially expressed proteins in the model and sham groups and the JTD and model groups. Integrating the network pharmacology and proteomics results revealed that JTD may regulate expressions of cytochrome c oxidase subunit 7C, metabotropic glutamate receptor 2, Slc30a1 zinc transporter 1, and apolipoprotein A-IV in VD mice and that their mechanisms involve biological processes like oxidative phosphorylation, regulation of neuron death, glutamate secretion, cellular ion homeostasis, and lipoprotein metabolism.
JTD may suppress VD development via multiple components, targets, and pathways. It may thus serve as a complementary treatment option for patients with VD.
血管性痴呆(VD)与脑血管损伤相关,以严重认知障碍为特征。健脾添精汤(JTD)已被广泛用于治疗VD。然而,其在该治疗中的分子靶点和作用机制仍不清楚。本研究整合网络药理学和蛋白质组学,以确定JTD治疗VD的靶点和机制,并为临床治疗提供新的见解和目标。
采用系统网络药理学方法确定JTD治疗VD的活性化学成分、潜在靶点和机制。然后,通过双侧颈总动脉短暂闭塞诱导VD小鼠模型,使用4D无标记定量蛋白质组学验证JTD针对VD的已确定靶点和机制。
通过在相关数据库中筛选活性化学成分和潜在靶点,确定了187种活性化学成分和416个疾病相关化合物靶点。实验表明JTD改善了小鼠的学习和记忆。蛋白质组学还确定了模型组与假手术组以及JTD组与模型组之间的112种差异表达蛋白。整合网络药理学和蛋白质组学结果显示,JTD可能调节VD小鼠中细胞色素c氧化酶亚基7C、代谢型谷氨酸受体2、溶质载体家族30成员1锌转运体1和载脂蛋白A-IV的表达,其机制涉及氧化磷酸化、神经元死亡调节、谷氨酸分泌、细胞离子稳态和脂蛋白代谢等生物学过程。
JTD可能通过多种成分、靶点和途径抑制VD的发展。因此,它可能作为VD患者的一种辅助治疗选择。